Wells Fargo & Co. Reiterates “Buy” Rating for Gilead Sciences (GILD)
In other Gilead Sciences news, EVP Norbert W. Bischofberger sold 90,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $80.90, for a total value of $7,281,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Gilead Sciences (NASDAQ:GILD) traded up 1.78% on Monday, hitting $81.20. The stock had a trading volume of 14,042,517 shares. Gilead Sciences has a 52 week low of $46.70 and a 52 week high of $84.88. The stock has a 50-day moving average of $80.73 and a 200-day moving average of $77.25. The company has a market cap of $124.7 billion and a P/E ratio of 29.55.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, April 22nd. The company reported $1.48 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The company’s quarterly revenue was up 97.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $6.28 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Nomura raised their price target on shares of Gilead Sciences from $120.00 to $121.00 in a research note on Thursday, April 10th. They now have a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note on Thursday, April 10th. They now have a $74.00 price target on the stock. Finally, analysts at Morgan Stanley initiated coverage on shares of Gilead Sciences in a research note on Wednesday, March 26th. They set an “equal weight” rating and a $75.00 price target on the stock. Two analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and an average price target of $94.91.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.